Topical erythromycin vs blank vehicle in a multiclinic acne study

Area of Science:

• Dermatology
• Pharmacology
• Formulation Science

Background:

• Acne vulgaris is a common skin condition characterized by inflamed papules and pustules.
• Topical antibiotics are a cornerstone of acne treatment, but formulation stability and efficacy are key.
• Erythromycin is a macrolide antibiotic with demonstrated anti-inflammatory properties relevant to acne treatment.

Purpose of the Study:

• To develop a stable topical solution of erythromycin for acne treatment.
• To evaluate the efficacy and safety of a 2% erythromycin solution compared to a blank vehicle in patients with facial acne.

Main Methods:

• Development of a stable erythromycin solution using ethanol, propylene glycol, and citric acid buffer.
• A 12-week, randomized, double-blind, controlled clinical trial comparing 2% erythromycin solution to the blank vehicle.
• Assessment of inflamed papule counts and overall treatment response.

Main Results:

• The erythromycin group showed a 56% reduction in inflamed papules versus 33% in the vehicle group.
• 62% of subjects in the erythromycin group achieved a good or excellent response, compared to 27% in the vehicle group.
• Adverse effects were mild and comparable between groups, including redness, dryness, and irritation; no infections or allergic reactions were reported.

Conclusions:

• A stable 2% erythromycin solution is a safe and effective topical treatment for moderately severe facial acne.
• The developed erythromycin formulation offers significant clinical improvement in acne lesions.
• Topical erythromycin demonstrates superiority over vehicle alone in reducing acne severity and improving patient outcomes.